Carolina Schinke

High Impact

Associate Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

Internal Med, College of Medicine

37 h-index 375 pubs 5,056 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Dr. Carolina Schinke's research focuses on plasma cell dyscrasias, including multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and plasma cell leukemia, as well as amyloid disease and Waldenström's macroglobulinemia. Her work investigates the molecular underpinnings of these conditions and their progression, as evidenced by publications examining the molecular makeup of smoldering myeloma and the spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.

Her clinical and research interests extend to the therapeutic landscape of multiple myeloma. This includes studies on the risk of infections associated with bispecific antibodies and the safety and efficacy of novel agents like teclistamab and talquetamab in relapsed or refractory multiple myeloma. Dr. Schinke also explores disparities in access to advanced therapies such as CAR-T cells and bispecific antibodies for multiple myeloma patients. Her work has also characterized the role of the immune microenvironment in multiple myeloma progression at a single-cell level.

With a career marked by extensive scholarship, Dr. Schinke has authored 369 publications, accumulating over 4,859 citations and an h-index of 36. She is recognized as a highly cited researcher. Her collaborations are primarily within the University of Arkansas for Medical Sciences, notably with Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, and Samer Al Hadidi, with whom she shares numerous publications.

Research Overview

Dr. Carolina Schinke is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at UAMS and joined the department in 2014. She completed her fellowship in Hematology/Oncology in 2013 at Montefiore Medical Center in New York and performed a research fellowship in molecular and translational science at Einstein, New York in 2014 . She earned her medical degree at the University of Halle in Germany and completed her residency at the Jacobi Medical Center in New York in 2010. Dr. Schinke has several publications and scientific poster presentations/abstracts and is a member of the American Society of Hematology, American Society of Oncology and International Myeloma Society. Her clinical interests are plasma cell dyscrasias, including MGUS, smoldering multiple myeloma, plasma cell leukemia as well as amyloid disease and Waldenstroms.

Metrics

h-index: 37
Publications: 375
Citations: 5,056

Selected Publications

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)

DOI OpenAlex
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis (2026)

DOI OpenAlex
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple <scp>CD38</scp> Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal? (2026)

DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

17 citations DOI OpenAlex
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study (2025)

58 citations DOI OpenAlex
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial (2024)

17 citations DOI OpenAlex
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024)

8 citations DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

24 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

8 citations DOI OpenAlex
Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (2024)

9 citations DOI OpenAlex
MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (2024)

13 citations DOI OpenAlex
Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers (2024)

8 citations DOI OpenAlex
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma (2024)

12 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

No FP attached UAMS Intramural Grant (CTSA) Principal Investigator
No FP attached UAMS Intramural Grant (CTSA) Principal Investigator
MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. - Pass Through: ICON Clinical Research Principal Investigator
MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. - Pass Through: ICON Clinical Research Principal Investigator
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc. Principal Investigator
Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
RC Pilot Award UAMS College of Medicine Principal Investigator
RC Pilot Award UAMS College of Medicine Principal Investigator